NASDAQ : MPLT
MapLight Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 7.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 429.04M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 44.09M | 30.73M | 14.42M | 7.61M | 4.10M |
| Research & Development | 198.84M | 138.35M | 68.52M | 49.67M | 27.14M |
| Operating Expenses | 242.93M | 169.08M | 82.95M | 57.28M | 31.25M |
| Operating Income | -242.93M | -169.08M | -82.95M | -57.28M | -31.25M |
| Interest & Investment Income | 8.84M | 5.52M | 4.50M | 1.10M | 429.00K |
| Earnings From Equity Investments | -986.00K | 986.00K | |||
| Currency Exchange Gain (Loss) | 4.00K | ||||
| Other Non Operating Income (Expenses) | 542.00K | 311.00K | 107.00K | -512.00K | 796.00K |
| EBT Excluding Unusual Items | -233.55M | -163.25M | -79.32M | -55.71M | -30.02M |
| Gain (Loss) on Sale of Investments | 3.72M | 2.10M | 1.74M | ||
| Pretax Income | -229.83M | -161.15M | -77.58M | -55.71M | -30.02M |
| Net Income | -229.83M | -161.15M | -77.58M | -55.71M | -30.02M |
| Net Income to Common | -229.83M | -161.15M | -77.58M | -55.71M | -30.02M |
| Shares Outstanding (Basic) | 30.98M | 8.68M | 736.18K | 659.67K | 557.02K |
| Shares Outstanding (Diluted) | 30.98M | 8.68M | 736.18K | 659.67K | 557.02K |
| EPS (Basic) | -7.42 | -18.56 | -105.38 | -84.45 | -53.89 |
| EPS (Diluted) | -7.42 | -18.56 | -105.38 | -84.45 | -53.89 |
| Free Cash Flow | -175.12M | -138.61M | -79.58M | -52.47M | -27.32M |
| Free Cash Flow Per Share | -5.65 | -15.97 | -108.11 | -79.54 | -49.05 |
| EBITDA | -242.34M | -168.50M | -82.25M | -56.73M | -30.67M |
| D&A For EBITDA | 585.00K | 578.00K | 701.00K | 556.00K | 574.00K |
| EBIT | -242.93M | -169.08M | -82.95M | -57.28M | -31.25M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 71.63M | 46.73M | 38.25M | 79.77M | 27.66M |
| Short-Term Investments | 233.09M | 258.37M | 70.54M | ||
| Cash & Short-Term Investments | 304.73M | 305.10M | 108.80M | 79.77M | 27.66M |
| Prepaid Expenses | 14.06M | 19.57M | 5.81M | 3.83M | 4.37M |
| Total Current Assets | 318.79M | 324.67M | 114.60M | 83.60M | 32.03M |
| Property, Plant & Equipment | 2.50M | 6.58M | 7.56M | 6.58M | 7.12M |
| Long-Term Investments | 46.62M | 147.99M | 11.38M | 986.00K | |
| Long-Term Deferred Charges | 3.00M | ||||
| Other Long-Term Assets | 448.00K | 266.00K | 373.00K | 234.00K | 234.00K |
| Total Assets | 368.35M | 479.51M | 136.92M | 91.41M | 39.39M |
| Accounts Payable | 2.05M | 3.29M | 1.91M | 3.25M | 3.60M |
| Accrued Expenses | 16.01M | 12.05M | 9.99M | 6.75M | 2.79M |
| Current Portion of Leases | 1.23M | 891.00K | 778.00K | 495.00K | 348.00K |
| Current Unearned Revenue | 3.24M | 4.20M | 5.86M | ||
| Total Current Liabilities | 19.29M | 16.23M | 15.92M | 14.70M | 12.60M |
| Long-Term Leases | 755.00K | 4.91M | 5.80M | 5.43M | 5.92M |
| Total Liabilities | 20.05M | 21.14M | 21.72M | 20.13M | 18.52M |
| Common Stock | 5.00K | 5.00K | |||
| Additional Paid-In Capital | 830.62M | 819.12M | 5.58M | 4.20M | 3.12M |
| Retained Earnings | -481.38M | -360.52M | -199.37M | -121.79M | -66.08M |
| Comprehensive Income & Other | -944.00K | -228.00K | 163.00K | ||
| Total Common Equity | 348.30M | 458.37M | -193.63M | -117.58M | -62.96M |
| Shareholders' Equity | 348.30M | 458.37M | 115.19M | 71.28M | 20.87M |
| Total Liabilities & Equity | 368.35M | 479.51M | 136.92M | 91.41M | 39.39M |
| Total Debt | 1.99M | 5.80M | 6.58M | 5.92M | 6.27M |
| Net Cash (Debt) | 302.74M | 299.30M | 102.22M | 73.84M | 21.39M |
| Net Cash Per Share | 9.77 | 34.48 | 138.85 | 111.94 | 38.41 |
| Filing Date Shares Outstanding | 46.38M | 44.02M | 761.36K | 667.37K | 557.02K |
| Total Common Shares Outstanding | 45.44M | 44.02M | 761.36K | 667.37K | 557.02K |
| Working Capital | 299.49M | 308.44M | 98.68M | 68.91M | 19.44M |
| Book Value Per Share | 7.67 | 10.41 | -254.32 | -176.19 | -113.03 |
| Tangible Book Value | 348.30M | 458.37M | -193.63M | -117.58M | -62.96M |
| Tangible Book Value Per Share | 7.67 | 10.41 | -254.32 | -176.19 | -113.03 |
| Machinery | 3.69M | 3.25M | 2.77M | 2.22M | |
| Leasehold Improvements | 5.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -229.83M | -161.15M | -77.58M | -55.71M | -30.02M |
| Depreciation & Amortization | 585.00K | 578.00K | 701.00K | 556.00K | 574.00K |
| Loss (Gain) From Sale of Assets | 11.00K | 7.00K | 59.00K | ||
| Loss (Gain) From Sale of Investments | -3.72M | -2.10M | -1.74M | 514.00K | -796.00K |
| Loss (Gain) on Equity Investments | 986.00K | -986.00K | |||
| Stock-Based Compensation | 53.91M | 36.01M | 1.08M | 1.04M | 1.36M |
| Other Operating Activities | 885.00K | 1.36M | 745.00K | 533.00K | 574.00K |
| Change in Accounts Payable | -43.00K | 1.38M | -1.34M | -405.00K | 1.33M |
| Change in Unearned Revenue | -2.41M | -3.24M | -959.00K | -1.66M | 1.86M |
| Change in Other Net Operating Assets | 5.94M | -10.98M | -761.00K | 4.11M | -1.46M |
| Operating Cash Flow | -174.67M | -138.14M | -78.81M | -52.01M | -26.58M |
| Capital Expenditures | -453.00K | -473.00K | -770.00K | -462.00K | -746.00K |
| Investment in Securities | -249.98M | -322.73M | -80.02M | ||
| Investing Cash Flow | -250.43M | -323.21M | -80.79M | -462.00K | -746.00K |
| Issuance of Common Stock | 276.74M | 276.00M | 294.00K | 40.00K | 12.00K |
| Other Financing Activities | -4.81M | -5.02M | -2.19M | -19.00K | |
| Financing Cash Flow | 463.26M | 469.82M | 118.06M | 104.57M | 33.17M |
| Net Cash Flow | 38.17M | 8.48M | -41.54M | 52.10M | 5.85M |
| Free Cash Flow | -175.12M | -138.61M | -79.58M | -52.47M | -27.32M |
| Free Cash Flow Per Share | -5.65 | -15.97 | -108.11 | -79.54 | -49.05 |
| Levered Free Cash Flow | -95.21M | -83.13M | -51.86M | -32.18M | |
| Unlevered Free Cash Flow | -95.21M | -83.13M | -51.86M | -32.18M | |
| Change in Working Capital | 3.49M | -12.84M | -3.06M | 2.04M | 1.72M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 421.26M | 766.56M | |||
| Enterprise Value | 118.53M | 1.05B | |||
| Last Close Price | 7.58 | 17.57 | |||
| PB Ratio | 0.99 | 1.67 | |||
| P/TBV Ratio | 1.21 | 1.67 | |||
| Debt / Equity Ratio | 0.01 | 0.01 | 0.06 | 0.08 | 0.30 |
| Net Debt / Equity Ratio | -0.87 | -0.65 | -0.89 | -1.04 | -1.02 |
| Net Debt / EBITDA Ratio | 1.25 | 1.78 | 1.24 | 1.30 | 0.70 |
| Net Debt / FCF Ratio | 1.73 | 2.16 | 1.28 | 1.41 | 0.78 |
| Quick Ratio | 15.79 | 18.80 | 6.83 | 5.43 | 2.20 |
| Current Ratio | 16.52 | 20.01 | 7.20 | 5.69 | 2.54 |
| Return on Equity (ROE) | -111.55% | -56.19% | -83.21% | -120.91% | |
| Return on Assets (ROA) | -67.11% | -34.29% | -45.41% | -54.74% | |
| Return on Capital Employed (ROCE) | -69.60% | -36.50% | -68.60% | -74.70% | -116.60% |
| Earnings Yield | -97.88% | -21.02% | |||
| FCF Yield | -41.57% | -18.08% | |||
| Buyback Yield / Dilution | -3,972.13% | -1,079.16% | -11.60% | -18.43% |